| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/04/2009 | WO2009070331A2 Compounds and methods for the selective inhibition of abcb1, abcc1 and abcg2 transporters and the treatment of cancers, especially drug resistant cancers and high throughput flow cytometry assay to detect selective inhibitors |
| 06/04/2009 | WO2009070328A1 Modulators of the epidermal growth factor receptor (egfr) pathway for use in the treatment or prevention of substance abuse |
| 06/04/2009 | WO2009070314A2 Crystalline form of sitagliptin |
| 06/04/2009 | WO2009070311A2 Crystal forms of o-desmethylvenlafaxine fumarate |
| 06/04/2009 | WO2009070307A1 Amorphous retapamulin and processes for preparation thereof |
| 06/04/2009 | WO2009070244A2 Methods for inhibiting fascin |
| 06/04/2009 | WO2009070241A2 Angiotensin ii receptor antagonists |
| 06/04/2009 | WO2009070164A1 Vigor enhancement via administration of pyrimidine derivatives |
| 06/04/2009 | WO2009070130A1 The 1,3-disubstituted ureas, method of re aration and utilisation thereof |
| 06/04/2009 | WO2009070116A1 A quinoline derivative acting as a p2x7-receptor antagonist |
| 06/04/2009 | WO2009070045A2 Imidazole derivatives, process for their preparation, and thier pharmaceutical use |
| 06/04/2009 | WO2009069993A1 Pharmaceutical composition combining various antispasmodic agents and a non-steroidal anti-inflammatory agent, which can be used to control and treat renal colic and inflammation |
| 06/04/2009 | WO2009069966A2 Use of compounds for controlling the function of sphingosylphosphorylcholine |
| 06/04/2009 | WO2009069916A1 Pharmaceutical formulation comprising hepatitis b virus neutralizing human antibody |
| 06/04/2009 | WO2009069887A1 A pharmaceutical composition comprising glabridin or glabridin derivatives for suppression of dendritic cell maturation |
| 06/04/2009 | WO2009069838A1 A composition for promoting osteoblast differentiation comprising berberine. |
| 06/04/2009 | WO2009069828A1 Agent for improving motor complications or psychiatric symptoms in parkinson's disease |
| 06/04/2009 | WO2009069800A1 Novel aminoglycoside antibiotic, method for producing the same, and pharmaceutical use of the same |
| 06/04/2009 | WO2009069764A1 Opioid analgesic agent |
| 06/04/2009 | WO2009069736A1 Nitrogenated compound |
| 06/04/2009 | WO2009069682A1 Therapeutic agent or preventive agent for hepatitis |
| 06/04/2009 | WO2009069680A1 Medicinal composition for treating gastrointestinal stromal tumor (gist) and kit and method for estimating the prognosis of patient suffering from gastrointestinal stromal tumor |
| 06/04/2009 | WO2009069668A1 Agent for increasing the expression of malignant melanoma antigen, and use thereof |
| 06/04/2009 | WO2009069643A1 Solid dispersion comprising 3-[5-[4-(cyclopentyloxy)- 2-hydroxybenzoyl]-2-[(3-hydroxy-1,2-benzisoxazol-6- yl)methoxy]phenyl]propionic acid or salt thereof, or composition comprising the solid dispersion |
| 06/04/2009 | WO2009069610A1 Fused indane compound |
| 06/04/2009 | WO2009069589A1 Novel naphthyridine derivative monohydrate and method for producing the same |
| 06/04/2009 | WO2009069352A1 Antimicrobial agent and external preparation for skin containing the same |
| 06/04/2009 | WO2009069291A1 Prophylactic and/or therapeutic composition for disease caused by inhalation of tobacco smoke |
| 06/04/2009 | WO2009069280A1 Method for producing granulated matter |
| 06/04/2009 | WO2009069140A1 An improved process for preparation of letrozole and its intermediates |
| 06/04/2009 | WO2009069139A1 Dosage form providing an ibuprofen-containing liquid fill |
| 06/04/2009 | WO2009069132A2 Novel reverse transcriptase inhibitors |
| 06/04/2009 | WO2009069131A1 Alginate biomaterials for the treatment of hepatic disorders |
| 06/04/2009 | WO2009069126A1 Compositions comprising nicotinic agonists and methods of using same |
| 06/04/2009 | WO2009069100A1 Phosphonic acid derivates and their use as p2y12 receptor antagonists |
| 06/04/2009 | WO2009069073A1 An improved process for the preparation of lamotrigine |
| 06/04/2009 | WO2009069044A1 Pyrazole derivatives as 5-lo inhibitors |
| 06/04/2009 | WO2009069032A2 Novel glucocorticoid receptor agonists |
| 06/04/2009 | WO2009069014A1 Amorphous lamivudine and its preparation |
| 06/04/2009 | WO2009069012A1 Process and intermediates for the preparation of substituted 1, 3-oxathiolanes, especially lamivudine |
| 06/04/2009 | WO2009068996A2 Conjugated beta-1,3-linked glucans |
| 06/04/2009 | WO2009068989A1 Benzomorphan compounds |
| 06/04/2009 | WO2009068967A1 Processes for preparing a substituted gamma-amino acid |
| 06/04/2009 | WO2009068955A2 Polymorphs of a c-met/hgfr inhibitor |
| 06/04/2009 | WO2009068922A2 Compositions containing capsaicinoids |
| 06/04/2009 | WO2009068916A1 Naphthalene diimide compounds interacting with g-quadruplex regions in dna |
| 06/04/2009 | WO2009068906A2 Combinations comprising zd4054 and a src family kinase inhibitor 172 |
| 06/04/2009 | WO2009068876A1 Compositions for the treatment of skin disorders |
| 06/04/2009 | WO2009068798A1 Compositions based on positively-charged cyclodextrins for preserving cells, tissues and organs, method for obtaining same and uses thereof |
| 06/04/2009 | WO2009068689A2 Combination of protein tyrosine phosphatase inhibitors and human growth hormone for the treatment of muscle atrophy and related disorders |
| 06/04/2009 | WO2009068682A2 Phenyl-oxetanyl-derivatives |
| 06/04/2009 | WO2009068668A1 New therapeutic approaches for treating cmt and related disorders |
| 06/04/2009 | WO2009068652A1 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators |
| 06/04/2009 | WO2009068651A1 Lipid emulsion for human consumption |
| 06/04/2009 | WO2009068623A1 Crystalline form of an antimalarial compound |
| 06/04/2009 | WO2009068617A1 1, 5-dihydro-pyrazolo (3, 4-d) pyrimidin-4-one derivatives and their use as pde9a modulators for the teatment of cns disorders |
| 06/04/2009 | WO2009068610A1 A method for producing adapalene gels |
| 06/04/2009 | WO2009068595A1 Novel carboxylic acid 4-phenylazo-phenyl ester derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 06/04/2009 | WO2009068567A1 C2-c5-alkyl-imidazole-bisphosphonates |
| 06/04/2009 | WO2009068557A1 Novel phenyl-acetamide and phenyl-propionamide derivatives useful as potassium channel modulators |
| 06/04/2009 | WO2009068552A1 Piperazinyl-sulfonamide derivatives useful in the treatment of gpr38 receptor mediated diseases |
| 06/04/2009 | WO2009068520A2 Polymorphic form of rotigotine |
| 06/04/2009 | WO2009068512A1 2 -amino-pyrimidine derivatives as histamine h4 antagonists |
| 06/04/2009 | WO2009068509A1 Novel benzamide derivatives useful as potassium channel modulators |
| 06/04/2009 | WO2009068482A1 Amino triazoles as pi3k inhibitors |
| 06/04/2009 | WO2009068468A2 Pyridine compounds |
| 06/04/2009 | WO2009068467A1 Aminothiazole derivatives |
| 06/04/2009 | WO2009068456A1 Means and methods for treating or preventing brain tumors based on the nuclear receptor tailless (tlx) |
| 06/04/2009 | WO2009068322A1 Selective inhibition of polo-like kinase 1 |
| 06/04/2009 | WO2009068320A1 Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10 |
| 06/04/2009 | WO2009068318A1 Mcp-i binding nucleic acids and use thereof |
| 06/04/2009 | WO2009068279A1 Smokeless compressed tobacco product for oral consumption |
| 06/04/2009 | WO2009068278A2 A pharmaceutical composition |
| 06/04/2009 | WO2009068246A2 Methods of treating obesity and metabolic disorders |
| 06/04/2009 | WO2009068214A2 Heteroaryl-substituted piperidines |
| 06/04/2009 | WO2009068190A2 Combinations comprising a prostaglandin and uses thereof |
| 06/04/2009 | WO2009068177A1 DERIVATIVES OF 4-(2-AMINO-1 -HYDROXYETHYL)PHENOL AS AGONISTS OF THE β2 ADRENERGIC RECEPTOR |
| 06/04/2009 | WO2009067891A1 Water-soluble triterpenephenol compounds having antitumor activity and the preparation thereof |
| 06/04/2009 | WO2009067856A1 Histone deacetylase inhibitor, composition and use thereof |
| 06/04/2009 | WO2009067808A1 Amplification of cancer-specific oncolytic viral infection by histone deacetylase inhibitors |
| 06/04/2009 | WO2009067797A1 Cysteine protease inhibitors for the treatment of parasitic diseases |
| 06/04/2009 | WO2009067791A1 Compositions and methods for producing vascular occlusion using a solid-phase platelet binding agent |
| 06/04/2009 | WO2009067790A1 STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION |
| 06/04/2009 | WO2009067755A1 Therapeutic targets and medicaments involving p230/golgin-245 |
| 06/04/2009 | WO2009054916A3 Oligomer conjugates of lidocaine and its derivatives |
| 06/04/2009 | WO2009052106A3 Formulation to improve gastrointestinal function |
| 06/04/2009 | WO2009051796A3 2,5-diaryl selenophene compounds, aza 2,5-diaryl thiophene compounds, and their prodrugs as antiprotozoal agents |
| 06/04/2009 | WO2009050555A3 Formulations of organo-platinic compounds in the presence of associative polymers, products thus obtained and uses thereof |
| 06/04/2009 | WO2009050267A3 Il24 for inducing hyperproliferative or autoimmune cell death |
| 06/04/2009 | WO2009050217A3 Improved pharmaceutical dry powder compositions for inhalation |
| 06/04/2009 | WO2009048289A3 Pharmaceutical composition for treating hepatitis c virus infection comprising hmg-coa reductase inhibitor and bile acid |
| 06/04/2009 | WO2009048251A3 Pharmaceutical composition containing micronized particles of naphthoquinone-based compound |
| 06/04/2009 | WO2009048249A3 Composition for preventing or treating lipid metabolic disorders comprising fucoxanthin or marine plant extract containing same |
| 06/04/2009 | WO2009047798A3 Acetamide derivatives as glucokinase activators, their process and medicinal applications |
| 06/04/2009 | WO2009047634A3 Aqueous formulations of acetaminophen for injection |
| 06/04/2009 | WO2009045992A3 C-met protein kinase inhibitors |
| 06/04/2009 | WO2009045309A3 Use of v2 receptor antagonists in combination with vasopressinergic agonists |
| 06/04/2009 | WO2009045308A3 Enhanced generation of cytotoxic t-lymphocytes by il-21 mediated foxp3 suppression |
| 06/04/2009 | WO2009042711A4 Polo-like kinase inhibitors |
| 06/04/2009 | WO2009040817A3 Salarins and tulearins, compositions and uses thereof |